Amgen released VESALIUS‑CV results showing its PCSK9 antibody Repatha reduced major cardiovascular events by 25% in high‑risk patients and cut first heart attacks by 36%, data published in the New England Journal of Medicine and presented at AHA. The trial enrolled patients already on statins and found benefits across endpoints including lower need for revascularization. Repatha’s results reinforce the clinical value of PCSK9 blockade for primary prevention in selected high‑risk populations and set a higher bar for oral rivals and other lipid‑lowering strategies.